Submitted:
18 November 2026
Posted:
20 November 2026
You are already at the latest version
Abstract
Allergic bronchopulmonary aspergillosis (ABPA) is a complex, progressive immune-allergic pulmonary disease that primarily affects patients with underlying predisposing conditions such as severe asthma and cystic fibrosis. Triggered by the non-invasive airway colonization of Aspergillus fumigatus, ABPA drives a hyper-amplified Type-2 and epithelial-mediated inflammatory cascade characterized by extreme elevations in total serum immunoglobulin E (IgE), profound local and systemic eosinophilia, and the formation of tenacious, high-attenuation mucus plugs. Historically, diagnostic recognition has been delayed by overlapping clinical features with severe asthma and atypical presentations mimicking thoracic malignancies, leading to irreversible lung injury. However, the revised 2024 International Society for Human and Animal Mycology (ISHAM) criteria, molecular component-resolved diagnostics, rapid on-site evaluation techniques, and the pheno-endotyping framework proposed by the European Academy of Allergy and Clinical Immunology (EAACI) Task Force now facilitate earlier and more accurate identification during the pre-bronchiectatic serological stage. While systemic corticosteroids, triazole antifungals, and airway clearance techniques remain foundational for acute exacerbations, targeted monoclonal antibodies—including anti-IgE, anti-IL-5/IL-5Rα, anti-IL-4Rα, and upstream anti-TSLP agents—have inaugurated a precision medicine paradigm for refractory and steroid-dependent disease. This comprehensive review synthesizes current advances in ABPA immunopathogenesis, diagnostic biomarkers, clinical-radiological phenotyping, and targeted biological strategies, while highlighting ongoing challenges in predictive biomarker validation and individualized biologic sequencing.
Keywords:
allergic bronchopulmonary aspergillosis
; Aspergillus fumigatus
; severe asthma
; Type-2 inflammation
; clinical phenotypes
; bronchiectasis
; biologics
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.